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Abstract
Background: We have showed that secretory Apolipoprotein J/Clusterin (sCLU) is down-regulated in senescent, stressed or
diseased red blood cells (RBCs). It was hypothesized that sCLU loss relates to RBCs vesiculation, a mechanism that removes
erythrocyte membrane patches containing defective or potentially harmful components.
Methodology/Principal Findings: To investigate this issue we employed a combination of biochemical and microscopical
approaches in freshly prepared RBCs or RBCs stored under standard blood bank conditions, an in vitro model system of
cellular aging. We found that sCLU is effectively exocytosed in vivo during membrane vesiculation of freshly prepared RBCs.
In support, the RBCs’ sCLU content was progressively reduced during RBCs ex vivo maturation and senescence under cold
storage due to its selective exocytosis in membrane vesicles. A range of typical vesicular components, also involved in RBCs
senescence, like Band 3, CD59, hemoglobin and carbonylated membrane proteins were found to physically interact with
sCLU.
Conclusions/Significance: The maturation of RBCs is associated with a progressive loss of sCLU. We propose that sCLU is
functionally involved in the disposal of oxidized/defected material through RBCs vesiculation. This process most probably
takes place through sCLU interaction with RBCs membrane proteins that are implicit vesicular components. Therefore, sCLU
represents a pro-survival factor acting for the postponement of the untimely clearance of RBCs.
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Introduction
Secretory Apolipoprotein J/Clusterin (sCLU) is a heterodimeric
glycoprotein that is found in all human fluids and tissues having a
ubiquitous expression pattern. sCLU exhibits an impressive
repertoire of binding partners [1]. It is characterized by an
extremely sensitive responsiveness to external stress stimuli [2].
sCLU reported physiological functions include complement
inhibition, clearance of cellular debris [3], chaperoning of
denatured proteins [4] and regulation of cell death [5].
The red blood cells (RBCs) aging process is a tightly regulated
and time-dependent, but not necessarily linear sum of molecular
events that leads to the non-random removal of senescent cells
from the circulation [6]. During aging RBCs lose water, energy,
proteins, membrane area and deformability. Membrane micro-
vesiculation is an integral part of the RBCs maturation that is
accelerated in older cells [7]. It is a process that challenges RBCs
by irreversible surface area and hemoglobin (Hb) loss. However, it
may also function in favour of the mature cells through the
scavenging of damaged, non-functional or signalling-effective cell
components that are released with the vesicles, preventing thus the
premature death of RBCs [8]. Despite the critical effect(s) of RBCs
aging in hematological and non-hematological diseases as well as
in transfusion medicine, many issues of the RBCs maturation and
senescence remain elusive.
Although RBCs storage in the cold, under blood banking
conditions, is far from being considered analogous to the
physiologic aging process in vivo, it has been widely used as a
model system for studying human RBCs aging, as stored RBCs
progressively express most of the molecular signals of in vivo aging
and erythrophagocytosis [9]. In fact, almost the whole set of
structural and functional deteriorations of stored RBCs that
collectively referred to as ‘‘RBCs storage lesion’’, exhibits
impressive resemblance to RBCs aging in vivo [10]. The main
biophysical effect of storage is the progressively increased
vesiculation and the subsequent changes in RBCs mechanical
and rheological properties. The oxidative mechanisms that drive
normal RBCs senescence [11,12] are probably related to the
storage lesions through their effect on the physiological aging and
vesiculation under storage [13,14]. Supportively, RBCs that have
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of mannitol exhibit a milder expression pattern of senescence
marks and vesiculation compared to those stored in autologous
plasma (Au-Pl) [15].
We have found (Antonelou et al., accompanying paper) that the
RBCs membrane-associated sCLU decreases during organismal
aging, following organism exposure to acute stress, in patients with
congenital hemolytic anemia, as well as during RBCs in vivo
senescence. To elucidate the biological role of sCLU in mature
RBCs we monitored sCLU levels and binding profile in
erythrocytes during their ex vivo aging in blood bank conditions.
We found that sCLU is progressively depleted from the stored
RBCs and is accumulated in the oxidized vesicles released from
them, probably through its physical interactions with an array of
vesicles-associated proteins. Our novel findings clearly imply a
functional role for sCLU in the physiology of the human RBCs
and in the molecular processes of aging and vesiculation.
Materials and Methods
Ethics
The study has been submitted and has been approved by the
Research Bioethics and BioSecure Committee of the Faculty of
Biology/University of Athens. Investigations were carried out in
accordance with the principles of the Declaration of Helsinki.
Written informed consent was obtained from all blood donors
participating in this study.
Subjects and RBCs storage in blood bank conditions
Venous blood of 22 healthy, adult, young and non-smoking
volunteers was used in the present study. Nine of them donated a
small volume of peripheral blood that was used in the
immunoprecipitation and confocal laser scanning microscopy
(CLSM) experiments, shortly after sampling. Eligible blood donors
(N=13) donated larger blood volume (450650 ml) and packed
RBCs were afterwards stored in anticoagulant, preservative and/
or additive solutions for 5–6 weeks at 4uC, according to the
standard blood banking protocols. Collection and processing of
blood for cold storage, as well as isolation, storage and sampling of
packed RBCs under various conditions were performed as
previously described [15]. Briefly, blood from seven donors was
collected in citrate-phosphate-dextrose-adenine (CPDA) double-
pack container systems. Packed RBCs were isolated and stored in
autologous plasma (Au-Pl) at 4uC. Blood from six different donors
was also collected in a quadruple citrate-phosphate-dextrose
(CPD)–saline-adenine-glucose-mannitol (SAGM) top-and-bottom
bag system and anti-coagulated with 70 ml of CPD (26.30 g/L
sodium citrate dihydrate, 3.27 g/L citric acid monohydrate,
2.51 g/L sodium phosphate dihydrate, 25.00 g/L glucose mono-
hydrate, pH 5.6). RBCs concentrates were also produced. SAGM
was then added to the units after leukodepletion by in-line
filtration. Au-Pl or CPD-SAGM units were stored at 4uC for the
whole storage period (35 or 42 days, respectively). For the storage
analyses, samples were withdrawn during the first 3–4 days of
storage and weekly thereafter. Four units of the Au-Pl-stored
RBCs were used for the collection of vesicles and sampled on the
first day of storage and afterwards on days 11, 17, 20, 27 and 34.
As controls, RBCs and vesicles of days 0–4 of the packed RBCs
units were used.
Erythrocytes and vesicles isolation - preparation of
membrane and cytosol fractions
Purified RBCs were isolated and fractionated in membrane and
cytosol preparations as described (Antonelou et al., accompanying
paper). Vesicles were isolated from the plasma of stored RBCs
concentrates by ultracentrifugation as detailed elsewhere [16].
Protein concentration was determined using the Bradford protein
assay. For the in vitro oxidation experiments 30 ml of packed
stored purified RBCs (CPD-SAGM leukodepleted units, day 42 of
storage) per sample were diluted in phosphate buffered saline
(PBS) containing 2.5 mM t-butyl hydroperoxide (tBHP). Following
incubation for 30 min at 37uC the cells pelleted and the
supernatant was centrifuged to collect the RBC-derived mem-
brane vesicles.
Immunoblotting and immunoprecipitation analyses
Equal amounts (12–200 mg) of RBCs fractions or vesicles
protein were loaded in Laemmli gels, blotted to nitrocellulose
membranes and probed with antibodies as previously described
[15]. Immunoblots were developed using chemiluminescence
(ECL) and quantified by scanning densitometry (Gel Analyzer
v.1.0 image-processing program). For immunoprecipitation ex-
periments, 1 mg of isolated RBCs membrane proteins were
resuspended in Nonidet P-40 (NP-40) containing lysis buffer
(50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.6 mM
phenylmethylsulfonyl fluoride and proteinase inhibitor cocktail) as
previously described [17]. Supernatants were incubated with the
specific primary antibodies, for two hours at 4uC. Following the
addition of Protein-G Sepharose, the precipitates were analyzed
by immunoblotting. For the detection of carbonylated components
into the immunoprecipitated material, the sCLU- and band 3-
related immunoprecipitates were derivatized by 2,4-dinitrophe-
nylhydrazine solution (at 1:4 v/v ratio) for 30 min at room
temperature before neutralization of the mixture with 1.5 vol of
neutralization solution (OxyblotH detection kit).
Confocal Laser Scanning Microscope (CLSM)
immunofluorescence co-immunolocalization and
Transmission Electron microscopy (TEM) immunogold
localization
For double immunofluorescence staining, RBCs were fixed with
90% methanol in PBS, permeabilized in PBS containing 0.05%
Triton X-100 and blocked with 3% bovine serum albumin and
0.1% Tween-20 in PBS [18]. Cells were probed with the
appropriate primary and secondary antibodies conjugated to
fluorescein isothiocyanate (FITC) or rhodamine. Slides were
observed under a Digital Eclipse C1 (Nikon, Melville, NY) CLSM
and recorded at the same exposure time. Controls were prepared
as described previously [15] and were free of immunoreactivity
(data not shown). sCLU localization in RBCs or vesicles by
immunogold TEM was done as previously described (Antonelou
et al., accompanying paper). Thin sections were probed with the
sCLU antibody and immunoglobulins G (IgGs) conjugated to
15 nm gold particles and examined on a Phillips EM 300 electron
microscope operating at 80 kV accelerating voltage.
Statistical analysis
Presented experiments have been analyzed for statistical
significance using the one-way analysis of variance (ANOVA),
the independent t-test or the chi-squared test as previously
described (Antonelou et al., accompanying paper); significance
was accepted at p,0.05. Individual protein levels were quantified
against a reference membrane protein further normalized to the
corresponding controls (samples stored for a short period). All
experiments shown have been repeated at least two times unless
otherwise stated.
CLU Involvement in RBC Maturation and Vesiculation
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The monoclonal antibodies against Band 3 (B9277) and actin
(A5316), the horseradish peroxidise (HRP)-conjugated secondary
antibodies (A-5420), as well as the Protease Inhibitor Cocktail,
tBHP, a-cellulose, microcrystalline cellulose (Sigmacell type 50)
and common chemicals and buffers were obtained from Sigma-
Aldrich (Germany). Polyclonal antibodies against Hb
(GR800GAP) and peroxiredoxin-2 (SP5464) were obtained from
Europa Bioproducts (Cambridge) and from Acris GmbH (Hid-
denhausen, Germany), respectively. Primary antibodies against
sCLU (sc-6419) and Band 3 (sc-20657) as well as secondary
antibodies conjugated to fluorescein isothiocyanate or rhodamine
were from Santa Cruz Biotechnology (Santa Cruz, CA). The
polyclonal antibody against CD59 was obtained from R&D
Systems (AF 1987). HRP-conjugated secondary antibodies (NA
934) and enhanced chemiluminescence Western blot detection kit
were from GE Healthcare Amersham (Piscataway, NJ). HRP-
conjugated secondary antibodies (P0161) were from DakoCyto-
mation (Glostrup, Denmark). The polyclonal antibody against
dinitrophenylhydrazone (DNP) residues was obtained from
Millipore (OxyblotH detection kit, S7150, Chemicon, Temecula,
CA). Unicryl acrylic resin and IgGs conjugated to 15 nm gold
particles were obtained from British Biocell International (Cardiff,
Wales, UK). Bradford protein assay was from Bio-Rad (Hercules,
CA). Quadruple CPD–SAGM top-and-bottom bag systems were
obtained from Baxter (Rome, Italy). Gel Analyzer v.1.0 image-
processing system and software was obtained from Biosure
(Athens, Greece). The monoclonal antibody against stomatin
and the antiserum against protein 4.1R were kindly provided by
Prof. R. Prohaska (Department of Medical Biochemistry, Medical
University of Vienna, Austria) and Prof. J. Delaunay (Service d’
He ´matologie, Ho ˆpital de Bicetre, Le Kremlin-Bicetre, France)
respectively.
Results
sCLU exocytosis during in vivo RBCs membrane
vesiculation
The continuous release of Hb-containing membrane vesicles
has been described as an integral part of the erythrocyte
maturation and senescence in vivo [7]. Since vesiculation is
accompanied by membrane surface and protein loss, we queried
whether the recently described selective loss of sCLU from the
membrane of senescent or stressed RBCs (Antonelou et al.,
accompanying paper) was associated with its exocytosis, as a
component of the released membrane vesicles. Considering the
low concentration and the technical difficulties in obtaining pure,
RBCs-derived vesicles from human plasma, for vesicles’ isolation
purposes we used the plasma of fresh (namely a few hours after
blood donation), leukodepleted packed RBCs units, from young,
healthy donors (N=2), collected in blood bank conditions
(SAGM). Immunogold localization analysis of sCLU in those
RBCs (N=2) demonstrated the presence of sCLU not only in the
membrane and the cytosol but also at the protrusions of budding
RBCs membrane areas (Fig. 1A). The same analysis in ultrathin
sections of RBC-derived vesicles (N=2) revealed sCLU-specific
immunogold particles primarily at the periphery (Fig. 1B; arrows),
yet at the cytosol of the vesicles too (Fig. 1B; dashed arrow).
Immunobloting analysis of purified vesicles verified the presence of
high amounts of the mature conventional sCLU isoform of
,40 kDa at the isolated vesicular material (N=2, Fig. 1C)
confirming thus sCLU exocytosis to vesicles released during RBCs
in vivo membrane vesiculation.
Progressive depletion of erythrocytes in sCLU during ex
vivo cellular aging is due to sCLU selective accumulation
in RBCs-derived vesicles
To ascertain whether sCLU exocytosis in RBCs-derived vesicles
is a continuous and progressive process during the cellular aging,
we firstly studied sCLU kinetics during RBCs storage in blood
bank conditions. As previously reported, the system of ex vivo RBCs
storage resembles in vivo cellular aging due to occurrence of
comparable cellular changes and extensive vesiculation (see
introduction). By using immunobloting analysis, sCLU was
detected in decreasing amounts in the membrane (Fig 2A1, upper
panel) and in the cytosol (Fig 2A1, lower panel) of leukodepleted
RBCs stored in units containing the additive solution SAGM
(N=4). The reduced levels of sCLU during RBCs senescence ex
vivo were mainly evident after the second half of the storage period
(days 25–42, p,0.050 vs. day 4, Figs 2A1,2 A 2), which coincides
with the previously reported increase in RBCs vesiculation
[9,15,16]. Compared to storage in autologous plasma, the addition
of mannitol-containing SAGM solution effectively reduces hemo-
lysis, vesiculation, oxidative stress, membrane instability and the
senescing rate of RBCs, thus ensuring longer and better storage of
RBCs [15,19]. Consequently, we then examined whether the
kinetics of sCLU membrane levels is diversified in RBCs stored in
the absence of the beneficial effects of mannitol. We found that, in
comparison to cells stored in SAGM, the RBCs stored in
autologous plasma (N=3) were characterized by a higher rate of
membrane sCLU loss during the storage period (Fig. 2B).
Compared to the first days of storage and starting on day 19,
the membrane levels of sCLU in Au-Pl RBCs were lower
(p,0.050) as compared to the expression levels in cells stored in
SAGM. The reduction in the sCLU membrane levels at the end of
the storage period, namely, day 42 for SAGM and day 35 for
autologous plasma, was found to be ,23% vs. ,58%,
respectively. To definitely demonstrate that sCLU is exocytosed
during the whole period of ex vivo cellular senescence we recorded
sCLU content in the exovesicles released into the supernatant of
the RBCs units from day 11 to day 34 of storage (N=4).
Figure 1. sCLU exocytosis to RBCs-derived vesicles. (A, B) TEM
immunogold localization of sCLU in RBCs membrane protrusions (A)
and vesicles (ves) (B) collected from fresh units of stored RBCs (N=2,
young healthy donors). Solid or dashed arrows indicate sCLU
immunogold localization at the periphery or the cytosol of the vesicles,
respectively. (C) Representative immunoblot analysis of RBCs-derived
purified vesicles (N=2) probed with either polyclonal anti-sCLU or with
monoclonal anti-Band 3 antibodies. Molecular weight markers are
indicated to the right of the blot. Bars in (A), (B), 100 nm.
doi:10.1371/journal.pone.0026033.g001
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released vesicles increased (by up to ,4.5 fold at the last week of
storage as compared to the first days) mainly after the second half
of the ex vivo erythrocytes lifespan (Fig. 3A); this pattern of sCLU
accumulation in RBCs-derived vesicles coincided with the
observed reduction of sCLU levels in the stored RBCs (see,
Fig. 2). TEM immunogold localization of sCLU in vesicles
collected after 35 days of storage in autologous plasma (N=2)
revealed that vesicular sCLU localizes primarily at the periphery
but also at the cytosol of the vesicles as well (Fig 3B).
Figure 2. Progressive decrease in the erythrocytes sCLU levels
during ex vivo cellular senescence. Representative sCLU immuno-
blot (A1) and densitometric analysis (A2) of membrane (A1, upper
panels) and cytosol (A1, lower panels) preparations derived from
leukoreduced RBCs units (N=4) stored for the indicated duration in
SAGM solution. (B) Comparative densitometric analysis of immunoblots
(not shown) of sCLU relative membrane levels in RBCs stored either in
SAGM (N=4; max 42 days of storage) or autologous plasma (Au-Pl)
(N=3; max 35 days of storage). Probing with anti-4.1R and anti-
peroxiredoxin-2 (Prx2) was used as a protein loading reference. Shown
densitometric data (mean values of at least two independent
experiments) indicate relative proportion against a loading reference
followed by normalization against the samples stored for a short period
(e.g. 4 days); error bars indicate 6 standard deviation. Asterisks and
dots indicate difference of each day of storage vs. day 4 and SAGM vs.
Au-Pl respectively, at significance level of p,0.05.
doi:10.1371/journal.pone.0026033.g002
Figure 3. Progressive sCLU accumulation in the RBCs-derived
vesicles released during ex vivo aging in blood bank storage
conditions. Representative sCLU immunoblot (A1) and densitometric
analysis (A2) of vesicle preparations derived from RBCs units stored in
autologous plasma (N=4). (B) TEM immunogold localization of sCLU at
the periphery and the cytosol of vesicles derived from RBCs stored in
autologous plasma for 35 days (N=2). (C) In vitro analysis of sCLU
oligomerization pattern (arrows) in vesicles derived from control (C) or
tBHP oxidized (Ox) RBCs; m, denotes an isolated plasma membrane
sample. Probing with anti-actin and anti-stomatin were used as protein
loading references. Shown densitometric data of sCLU vesicular levels
(mean values of at least two different experiments) indicate relative
proportion against a loading reference followed by normalization
against the controls, namely samples stored for a short period of 11
days; error bars indicate 6 standard deviation. Asterisks indicate
difference of each day of storage vs. day 11 at significance level of
p,0.05. Bars in (B), 100 nm.
doi:10.1371/journal.pone.0026033.g003
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and vesiculation processes are accompanied by a progressive
increase in the membrane proteome oxidative defects [15,20,21].
As shown in Fig. 3C, exposure of isolated stored RBCs (N=3, on
27 day of storage) to the oxidant tBHP resulted in increased sCLU
presentation and oligomerization in vesicles derived from the
oxidized RBCs, implying a role of oxidative stress into sCLU
exocytosis to vesicles.
sCLU binds to Band 3, CD59, Hb and a range of
carbonylated-oxidized RBCs membrane proteins
The previous results outlined a probable role for sCLU in the
molecular processes of senescence and vesiculation in RBCs.
Considering the chaperone function of sCLU [4] we screened for
sCLU binding partners among a group of RBCs proteins that are
functionally implicated in those processes. By using co-immuno-
precipitation analysis (N=6, young subjects), we showed that
immunoprecipitation of sCLU or Band 3 in membrane prepara-
tions resulted in co-immunoprecipitation of Band 3 or sCLU
respectively, indicating a physical interaction of Band 3 and sCLU
in RBCs plasma membrane (Fig. 4A1). Subsequent CLSM
immunofluorescence co-immunolocalization studies verified the
co-localization of the two proteins at the RBCs plasma membrane
(N=3, Fig. 4A2). By applying the same analysis we also found that
sCLU interacts with CD59 (Fig. 4A1, lower panel), a glycosyl
phosphatidylinositol-anchored complement regulation protein that
localizes at the extracellular side of the RBCs membrane as well as
with Hb (Fig. 4A3). On the contrary, sCLU does not bind stomatin
(Fig. 4A1) a protein embedded at the cytosolic side of the RBCs
membrane and exocytosed through vesiculation. In accordance to
our recent studies showing that sCLU does not distribute in the
RBCs cytoskeleton (Antonelou et al., accompanying paper) we
found no sCLU interaction with several cytoskeleton constituent
proteins examined (data not shown). As it has been proposed that
sCLU binds and stabilizes stressed proteins in a folding-competent
state [4] we asked whether sCLU also binds carbonylated proteins
at the RBCs plasma membrane. By applying limited 2,4-
dinitrophenylhydrazine (DNPH) modification of the sCLU- or
Band 3-immunoprecipitated material followed by dinitrophenyl-
hydrazone (DNP) immunoblotting, we detected a range of
carbonylated-oxidized bands in association to both sCLU and
Band 3 proteins (Fig. 4B).
Discussion
sCLU is a primarily secreted protein sorted for secretion
through the classic endoplasmic reticulum- and Golgi-associated
secretory pathway [5,17,22,23]. Our currently reported findings
provide evidence that sCLU is also a ‘‘secreted’’ component of
mature RBCs through the membrane exovesiculation process.
Furthermore, in common to the protective role that sCLU exhibits
in other mammalian tissues, wherein it functions to alleviate cells
from the deleterious effects of increased oxidative stress [1,2], the
pattern of sCLU protein interactions and exovesiculation,
delineates its active implication in the disposal of oxidized/
defected molecules from maturing RBCs.
We have reported a significant loss of sCLU membrane levels in
senescent or stressed RBCs in vivo, both in physiological conditions
as well as in hemolytic disease (Antonelou et al., accompanying
paper). The blood bank storage has been widely used as an
alternative model system of in vivo aging [9]. In fact, some aspects
of the erythrocyte aging may be more pronounced and therefore
easier studied in units of stored cells than in freshly obtained cells
because of the absence of an immunological removal system [24].
Our studies on sCLU of RBCs stored in blood bank conditions
verified that prospect and indicate that the decrease in the sCLU
levels refers to both the membrane and the cytosolic sCLU.
Moreover, the gradual loss of sCLU from RBCs is a progressive
and continuous process, throughout the maturation stages, related
to endogenous RBCs-specific molecular processes of aging, redox
imbalance and vesiculation rate.
According to both in vivo (Antonelou et al., accompanying
paper) and currently reported ex vivo data, the decrease in the
RBCs sCLU levels takes place via selective sorting and exocytosis
of sCLU through vesiculation and is an aging- and oxidative stress-
related mechanism. Supportive information resulted by both the
analysis of the RBCs-derived vesicles and the co-immunoprecip-
itation experiments. Indeed, by in situ approaches we demonstrat-
ed the constant localization of sCLU at both the membrane and
Figure 4. sCLU interactions in RBCs membrane. Purified RBCs
membranes from healthy subjects (N=6) were lysed in NP-40 and
lysates were immunoprecipitated (IP) with polyclonal antibodies against
sCLU, Band 3, stomatin or normal serum (control). Immunoprecipitates
were immunoblotted (IB) under reducing conditions for sCLU (A1, upper
panel), Band 3 (A1, middle panel), CD59 (A1, lower panel) and Hb (A3);
shown IPs are representatives from two independent experiments. (A2)
CLSM co-immunolocalization of the sCLU and Band 3 proteins at the
RBCs plasma membrane. Cells were co-stained with anti-Band 3
monoclonal (green; upper panel) and anti-sCLU polyclonal antibodies
(red; lower panel). Captured images were merged to reveal co-
distribution sites (yellow; lower panel, arrows). Bars, 3 mm. (B) Anti-
dinitrophenylhydrazone (DNP) immunoblotting of sCLU, Band 3, and
control (IgGs) immunoprecipitates for the detection of co-immunopre-
cipitated carbonylated proteins (arrows) in 2,4-dinitrophenylhydrazine-
modified (OX) or unmodified protein material.
doi:10.1371/journal.pone.0026033.g004
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very first day of storage and furthermore the progressive
accumulation of the protein into the vesicles towards the
completion of the storage period. The monitoring of sCLU
accumulation in vesicles coincides with the progressive depletion
seen in the stored RBCs and the previously documented
progressive increase in vesiculation and proteome carbonylation
defects [16,20,21]. In addition, the co-immunoprecipitation
analyses of sCLU not only verified the previously reported data
on patients with hemolytic anemia (Antonelou et al., accompany-
ing paper), which indicated that membrane association of the
protein in RBCs may depend on factors other than IgGs, but also
demonstrated that all of the observed physical interactions of
sCLU are known components of the RBCs-derived vesicles,
namely Band 3, CD59, Hb and carbonylated proteins.
A central role for sCLU in the regulatory networks of aging RBCs
has been recently predicted following in silico establishment of the
interactome models of RBCs proteins [25]. Specifically, it was
predicted that sCLU interacts with several proteins in the core of the
network, including chaperones, caspases and CD59 in the ‘‘Cell
Death’’ sub-network [25]. CD59 is a glycosyl phosphatidylinositol-
anchored and highly mobile complement regulation protein of the
RBCs surface and a component of RBCs-derived vesicles [8]. Apart
from its role in membrane vesiculation [26], CD59 has been also
implicated in the inhibition of the lytic membrane attack complex
assembly [27]. Although the functional consequences of the sCLU
binding to CD59 are not clear, the currently observed sCLU-CD59
physical interaction may relates to the recently reported sCLU-
mediated inhibition of the membrane attack complex and rabbit
erythrocytes hemolysis [28]. On the other hand, Band 3 plays a key
role in regulating RBCs metabolism, membrane structure and ion
exchange while its modifications are tightly associated with RBCs
aging, vesiculation, erythrophagocytosis and cell death [9,11,24].
Specifically, the recognition and removal of senescent RBCs is
triggered by binding of autologous IgGs to a neo-antigen that
originates fromBand 3 proteinmodifications. The Hbpresent inthe
sCLU-immunoprepicipated material represents either independent
binding of intracellular sCLU to the membrane or cytosolic Hb or
most probably the co-immunoprecipitated Band 3-bound Hb
molecules. Overall, the binding profile of sCLU in RBCs membrane
implies a specific role for sCLU in the exovesiculation process and
the management of stress imposed by either endogenous or
exogenous factors in RBCs. The comparative monitoring of sCLU
membrane levels in two storage systems (Au-Pl and SAGM) that
differ between each other in vesiculation degree, membrane
proteome oxidation defects and cellular aging progression [15,19],
further supported the impact of all of these parameters on the sCLU
loss in stressed, maturing or senescent RBCs.
Moreover, our co-immunoprecipitation data documented the
physical association of sCLU with a range of carbonylated proteins
in the RBCs membrane. Considering that, sCLU functions as a
chaperone involved in the quality control of protein folding [29]
and in the clearance of cellular debris by non-professional
phagocytes [3] we propose that it also contributes to the
scavenging of oxidized or aggregated molecules that are selectively
removed from senescent or stressed RBCs via vesiculation. By
assuming that, sCLU represents not only a molecular biomarker of
cellular senescence and oxidative stress but also a pro-survival
factor that contributes to the transient inhibition or delay of the
premature removal of otherwise functional RBCs from the
circulation; this proposed function of sCLU is further supported
by the recently predicted role of the protein in the RBCs death
regulatory pathways [25]. Such a lifetime-extension mechanism
might be especially beneficial to individuals with hemolytic
diseases and to those who receive transfusion of long-term stored
RBCs.
Taken together, our results (summarized in Fig. 5) provide novel
evidence for an emerging role of sCLU in the physiology of mature
human erythrocytes and the molecular processes involved in RBCs
aging and vesiculation. The maturation of RBCs is associated with
a progressive loss of sCLU. We propose that during RBCs aging
sCLU, most probably through its interaction with Band 3, CD59,
Hb and carbonylated membrane molecules, is actively involved in
the disposal of oxidized and/or defected material through
Figure 5. Proposed model of sCLU involvement in RBCs plasma membrane integrity, cellular senescence and vesiculation.
Erythrocytic sCLU localizes at both sides of the plasma membrane in association with non-cytoskeletal areas, as well as in the cytosol (see also,
Antonelou et al., accompanying paper). At the intracellular side of the RBCs membrane sCLU may bind Band 3, Hb and/or other cytoskeleton-free
membrane portions. On the other hand, the sCLU that localizes at the extracellular side of the RBCs membrane can attach to membrane by binding
to Band 3, CD59, plasma membrane IgGs or to an currently unknown sCLU-specific receptor. Physiological in vivo or ex vivo RBCs senescence (1) is
associated with cytosol, cytoskeleton and membrane structural alterations, including Band 3 modifications, increased membrane binding of IgGs,
proteolysis, protein aggregation and increased oxidation defects. Vesiculation (2), a self-protective mechanism of mammalian erythrocytes, removes
oxidized proteins and aggregates from both plasma membrane and cytosol thereby postponing the untimely elimination of otherwise healthy
erythrocytes. This process takes place through the entire in vivo or ex vivo lifespan of RBCs and is functionally connected to the release of sCLU-, Band
3-, CD59-, Hb- and IgGs-containing vesicles. We propose that vesicular sCLU by following its membrane linkers (e.g. Band 3) or other unknown
cytosolic interacting proteins assists via its chaperone function in the disposal of non-functional or death signalling effective material from RBCs.
doi:10.1371/journal.pone.0026033.g005
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blood aging as well as of in vitro labile blood products storage
lesions evaluation and post-transfusion effects, our data might be
of high interest for the transfusion medicine community. Indeed,
sCLU content in stored RBCs would appear to be a useful tool in
assessing the impact of changes in the blood banking manufac-
turing process. Work in progress in our lab aims to investigate
these issues in a well-controlled setting, by using a murine RBCs
storage and transfusion model.
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